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Abstract
Background:  Cervical smears exhibiting unequivocal features of 'low grade squamous
intraepithelial lesion' (LSIL) are occasionally also admixed with some cells suspicious for, but not
diagnostic of, 'high grade squamous intraepithelial lesion' (HSIL). Only a few studies, mostly
reported as abstracts, have evaluated this concurrence. In this study, we evaluate the current
evidence that favors a distinct category for "LSIL, cannot exclude HSIL" (LSIL-H), and suggest a
management algorithm based on combinations of current ASCCP guidelines for related
interpretations.
Methods: We studied SurePath™ preparations of cervical specimens from various institutions
during one year period. Cytohisto correlation was performed in cases with cervical biopsies
submitted to our institution. The status of HPV DNA testing was also noted in some LSIL-H cases
with biopsy results.
Results: Out of 77,979 cases 1,970 interpreted as LSIL (1,523), LSIL-H (146), 'atypical squamous
cells, cannot exclude HSIL' (ASC-H) (109), and HSIL (192) were selected. Concurrent biopsy
results were available in 40% (Total 792 cases: 557 LSIL, 88 LSIL-H, 38 ASCH, and 109 HSIL). Biopsy
results were grouped into A. negative for dysplasia (ND), B. low grade (HPV, CIN1, CIN1 with
HPV), and C. high grade (CIN 2 and above).
The positive predictive values for various biopsy results in relation to initial cytopathologic
interpretation were: a. LSIL: (557 cases): ND 32% (179), low grade- 58% (323), high grade- 10%
(55); b. LSIL-H: (88 cases): ND 24% (21), low grade- 43% (38), high grade- 33% (29); c. ASCH: (38
cases): ND 32% (12), low grade- 37% (14), high grade- 31% (12); d. HSIL (109 cases): ND 5% (6),
low grade 26% (28), high grade 69% (75). The patterns of cervical biopsy results in cases reported
as LSIL-H were compared with that observed in cases with LSIL, ASC-H, and HSIL.
94% (32 of 34) of LSIL-H were positive for high risk (HR) HPV, 1 was negative for HR HPV but
positive for low risk (LR), and 1 LSIL-H was negative for HR and LR both.
Conclusion: LSIL-H overlapped with LSIL and ASC-H, but was distinct from HSIL. A management
algorithm comparable to ASC-H and HSIL appears to be appropriate in LSIL-H cases.
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Background
Cervical smears may exhibit unequivocal 'low grade squa-
mous intraepithelial lesion' (LSIL) in association with
atypical cells cytomorphologically suspicious for, but not
sufficient to be interpreted as, 'high grade squamous
intraepithelial lesion' (HSIL) [1,2]. This concurrence has
been identified recently by many laboratories, but its
reporting is not addressed in the 2001 Bethesda System
terminology (Bethesda 2001) [3-5]. Lack of a standard-
ized method of reporting, however, may affect proper
application of American Society for Colposcopy and Cer-
vical Pathology (ASCCP) guidelines based on Bethesda
2001 [6,7]. Although 'atypical squamous cells, cannot
exclude HSIL' (ASC-H) is not a definitive interpretation, it
is related to an increased risk of higher-grade lesions on
biopsy [3]. On the contrary, LSIL is a definitive interpreta-
tion with relatively lower prevalence of high-grade lesion
on subsequent biopsy.
Currently, the reporting pattern to communicate this con-
currence varies amongst different cytopathology laborato-
ries. In our institution, for statistical and quality assurance
reasons, we report this concurrence under definitive inter-
pretation as LSIL with a comment that ASC-H cells are
also present. Others essentially follow a reverse approach
and report it as ASC-H with LSIL in the comment. Some
interpreters may choose to combine the associated ASC-H
component with LSIL and report the combination as
HSIL, which may lead to a potentially high false positivity
rate. Rarely, the ASC-H component may be downgraded
to 'atypical squamous cells of undetermined significance'
(ASCUS) with the final interpretation as LSIL, with poten-
tially false negative results for high-grade lesions.
In the current study, we evaluated cervical biopsies in
cases of "LSIL with ASC-H" (LSIL-H) (Figure 2 &3) in
comparison to other categories in Bethesda 2001, to see if
this designation as a distinct category is justified.
pv dna testing
Materials and methods
We studied SurePath™ [TriPath Imaging Inc, Burlington,
NC] preparations of cervical specimens over a one year
period (Figure 1). Initial cytopathologic interpretations
were performed by more than five different cytopatholo-
gists, based on Bethesda 2001 criteria and were represent-
ative of general cytology reporting patterns [4].
LSIL-H was defined as cases with unequivocal LSIL, in
concurrence with ASC-H (Figure 2 and 3). ASC-H cells
showed cytomorphologic features reported previously [8].
As observed in a subset of ASC-H, some of these cases
showed small atypical parakeratotic (SAPK) cells (Figure
3), which may demonstrate superficial resemblance to
high grade cells in liquid based cytology [9,10].
The cytology results were correlated with concurrent biop-
sies (both colposcopically-guided and LEEP biopsies) per-
formed at the time of, or within 3 months of cytologic
interpretation. Many institutions, in addition to our pri-
mary hospital, submitted cervical cytology specimens.
Cervical biopsies from some outside institutions were not
sent to our institution for surgical pathology and the cyto-
histo correlation was available in only a fraction of cases.
The cervical biopsy results for cases with cytologic inter-
pretation as LSIL, LSIL-H, and ASC-H were compared
using the Chi-square test for statistical analysis.
In addition, the status of HPV DNA testing (Hybrid Cap-
ture (HC) II, Digene, Silver Spring, MD, USA) performed
within a year of biopsy was noted in LSIL-H cases with
biopsy results.
Results
We studied 77,979 cases over a one year period (Figure 1).
Out of these 1,970 cases (ages 16 to 65 years) were inter-
preted as abnormal (1,523 LSIL, 146 LSIL-H (Figure 2
&3), 109 ASC-H, and 192 HSIL). The cyto-histo correla-
tion was available in 40% (792 of 1,970) cases. These
included 557 LSIL, 88 LSIL-H, 38 ASC-H, and 109 HSIL
(Figure 1).
The biopsy results were grouped into: A. negative for dys-
plasia (ND), B. low grade (HPV, CIN1, or CIN1 with
HPV), and C. high grade (CIN 2 and above) (Table 1).
Positive predictive value (PPV) for each category of biopsy
result was calculated for LSIL, LSIL-H, ASC-H, and HSIL
interpretations (Table 1).
LSIL-H (Figure 2 &3) had a lower prevalence of negative
biopsy results, compared to ASC-H and LSIL (24% nega-
tive results with LSIL-H versus 32% with ASC-H and 32%
with LSIL) (Table 1). LSIL-H had a higher chance of asso-
ciation with high grade dysplasia on biopsy, comparable
to that for ASC-H (Positive predictive value [PPV] of 33%
with LSIL-H and 31% with ASC-H). LSIL alone was asso-
ciated with a significantly lower risk (PPV 10%) for high
grade dysplasia as compared to LSIL-H (PPV 33%). PPV of
LSIL-H (33%) was lower for high grade lesions as com-
pared to HSIL (69%). LSIL-H was associated with higher
number of negative biopsy results (24%) as compared to
HSIL (5%). However, as compared to ASC-H (32%), the
prevalence of negative biopsy results with LSIL-H was rel-
atively lower (24%) (Table 1, Figure 4).
PPVs between different groups were compared by per-
forming two separate 2 × 3 Chi-square tests for LSIL versus
LSIL-H and LSIL-H versus ASC-H (Table 1). Applying the
Bonferroni correction for multiple testing, the significance
level was adjusted to 0.025. The differences between LSIL
and LSIL-H were statistically significant (Chi-square valueCytoJournal 2007, 4:7 http://www.cytojournal.com/content/4/1/7
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of 35.7 with p value less than 0.001). However, for LSIL-
H and ASC-H the difference was not significant (Chi-
square is 0.87 with p value nearly equal to 1) (Table 1).
Thus, the pattern of biopsy results for LSIL-H overlapped
on the lower side with LSIL, but was statistically different.
On the higher side, it approached ASC-H, without a statis-
tically significant difference, but slightly higher prevalence
of negative results as compared to LSIL-H.
Results of HPV DNA testing (HPVT) performed within
one year of the concurrent cervical biopsy were available
in 34 of 88 LSIL-H cases. 94% (32 out of 34) of LSIL-H
cases were positive for high risk HPV. Two cases were neg-
ative for high risk HPV. One was negative for both high
and low risk HPV, but the biopsy showed mild dysplasia
with HPV. The other case was positive for low risk HPV
only, but the biopsy showed high grade dysplasia- (not
graded).
Discussion
Lack of a standardized method for reporting LSIL-H gen-
erates some questions because of the risk of compromis-
ing quality assurance program. More significantly, the
proper application of current management guidelines is
predominantly based on Bethesda 2001 [6,7] which does
not have LSIL-H category. Accumulating evidence, based
on our study and a few other studies [1,2,11-14], favor
LSIL-H (Figure 2 &3) as a distinct category to address these
issues. In the current study, LSIL-H accounted for 0.19%
(146 out of 77,979) of all Pap tests. This rate was compa-
rable to that reported by Elsheikh et al (0.15%) [14],
Booth et al. (0.15%) [3], and McGrath et al (0.2%) [12].
LSIL-H (Figure 2 &3) had an increased risk of high grade
dysplasia on biopsy, which was comparable with ASC-H
(33% and 31% respectively), but less than that for HSIL
(Table 1, Figure 4). This group, however, had a lower
chance of a negative biopsy result as compared to the ASC-
H group (24% in LSIL-H versus 32% in ASC-H). As com-
pared to LSIL-H, LSIL alone was associated with a signifi-
cantly lower risk for high grade dysplasia (33% in LSIL-H
versus 10% in LSIL). Thus, LSIL-H cytology showed an
increased risk of high grade dysplasia on biopsy, with a
PPV higher than that for LSIL cytology, but comparable
with ASC-H, and distinctly lower than that for HSIL cytol-
ogy (Table 1, Figure 4). This confirms the intermediate
status of LSIL-H, which overlaps on one side with LSIL,
and on other side with ASC-H (Figure 4).
Review of the literature (Table 2) also shows a higher pre-
dictive value of LSIL-H for a high grade lesion on biopsy,
with overlap on one side with LSIL and on the other with
ASC-H, but is distinct from HSIL [1,2,11-13,15-18]. How-
ever, most of these studies are reported as abstracts
[11,13,15-18] with availability of only partial data for
analytical review (Table 2). There are no reports on the use
of SurePath liquid based cytology for diagnosis of LSIL-H
as reported by this study. Other studies are based on con-
LSIL-H (with CIN2 & HPV in biopsy) Figure 2
LSIL-H (with CIN2 & HPV in biopsy): Cervical smear with unequivocal LSIL in other fields. This field shows rare LSIL (a & 
c) with some groups of cells consistent with ASC-H. The cells have a high N/C ratio with rounder curving cell borders (better 
seen in 'b'). At 20X (a), the ASC-H cell is difficult to focus because of three dimensional component in liquid based cytology. (a through 
c- Papanicolaou stained SurePathTM preps)
20X a 40X 40X b c
ASC-H
LSIL
ASC-H
LSILCytoJournal 2007, 4:7 http://www.cytojournal.com/content/4/1/7
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ventional cervical smears or other liquid based cytology
such as ThinPrep (Table 2).
The abstract reported by Booth et al showed association of
LSIL-H cytologic interpretation with high grade dysplasia
in 45% of cases on biopsy, as compared to 10% in the
LSIL group [13]. These researchers evaluated LSIL-H with
reference to ThinPrep imaging [16]. Their abstract showed
post-imaging increases in the interpretation of LSIL-H,
with a higher predictive value as compared to pre-imaging
figures (64% versus 23% with statistically significant dif-
ference) [16]. Another abstract by Jain et al reported the
significance of number of ASC-H cells in association with
LSIL, with the conclusion that the PPV for high grade dys-
plasia on biopsy increases with higher numbers of ASC-H
cells in the smear [18]. Additional abstracts reported vari-
able overlap of LSIL-H with ASC-H and LSIL [15,17].
McGrath et al reported 58 cases initially interpreted as
mild to moderate dysplasia in conventional cervical
smears, with follow-up biopsies showing high grade dys-
plasia in 59% and low grade dysplasia in 41% [12]. How-
ever, this study did not use the current LSIL-H
terminology. Based on univariate and multivariate logistic
regression analysis, they did not find any specific morpho-
logic features or relationship with the volume of LSIL-
HSIL components for definitive interpretation. Nasser et
al used a slightly different approach than our study, and
compared 144 LSIL-H cases with 155 LSIL cases (average
follow-up, 3–4 months) [12]. They reported a higher inci-
dence of high grade dysplasia on biopsy in cases with
LSIL-H as compared to LSIL cytology (29% for LSIL-H
vs.15% for LSIL). Out of 21,342 cases evaluated by Kir et
al, 13 LSIL-H interpretations were associated with high
grade dysplasia on biopsy in 61% of cases, as compared to
only 11% high grade dysplasia on biopsy in 27 cases with
LSIL cytology [2]. A study by Elsheikh et al [14] evaluated
LSIL-H in ThinPrep. All these studies recommended LSIL-
H as a distinct cytologic diagnosis (Table 1). Our results
with SurePath are comparable to those reported by
Elsheikh et al for ThinPrep [14] and Underwood et al [15]
for conventional smears and ThinPrep.
A subset of LSIL-H is associated with HPV, CIN1 or CIN1
with HPV on biopsy (Figure 4). As observed in a subset of
ASC-H, some of these cases may be unequivocal cases of
LSIL with small atypical parakeratotic (SAPK) cells (Figure
3) which may demonstrate a superficial resemblance to
high grade cells in liquid based cytology [9,10,19]. Care-
ful scrutiny with reference to the morphological spectrum
of ASC-H reported previously should facilitate improved
interpretation even with cytomorphology [8]. Some of the
LSIL-H (with only HPV in biopsy) Figure 3
LSIL-H (with only HPV in biopsy): Cervical smear (a, b) showed unequivocal LSIL cells in other fields. This field shows rare 
LSIL (a & b) along with some groups of cells consistent with ASC-H. The biopsy (c) showed only human papilloma virus cyto-
pathic effect. Small atypical parakeratotic (SAPK) cells with distinct and sharp angulated cell borders with tinge of cytoplasmic 
eosinophilia (arrowhead in b) (see also corresponding area in a) were interpreted as ASC-H component. (a & b- Papanicolaou 
stained SurePathTM preps, c- HE stained cervical biopsy section).
20X a 40X 40X b c
ASC-H
LSIL
SAPKCytoJournal 2007, 4:7 http://www.cytojournal.com/content/4/1/7
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Study plan Figure 1
Study plan.
Total cases studied
77,979
(During one year period)
Total 1,970 cases 
(16-65 years of age)
HSIL
192
ASC-H
109
LSIL-H
146
LSIL
1,523
Selected cases with cytological interpretations as
Total 792 cases 
HSIL
109
ASC-H
38
LSIL-H
88
LSIL
557
Cases with concurrent biopsy*
(Performed at the time of cytology or within 3 months of cytology)
(*Cervical cytology specimens were from many institutions in addition to our primary 
hospital. All institutions did not submit the surgical pathology to us. Because of this cyto-
histo correlation could not be performed in all the cases.) 
Comparison of PPV (Table 1, Figure 4). 
Chi-square test was applied for statistical comparison. 
PPV for negative for dysplasia, low grade (HPV, CIN-1, CIN1 with HPV), and 
high grade (CIN 2 and above) biopsy diagnoses were calculated (Table 1).CytoJournal 2007, 4:7 http://www.cytojournal.com/content/4/1/7
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ASC-H patterns may represent hyperchromatic crowded
groups which should be scrutinized carefully for proper
interpretation as reported previously [21,22].
The management of LSIL-H cases has not been addressed
currently by the ASCCP guidelines [6,22-25]. Based on the
biopsy pattern in this study and review of the literature,
the initial management may be similar to that of LSIL with
referral to colposcopy [6,7], but the subsequent approach
may be comparable to HSIL (and ASC-H) (Figure 5). Or,
the management may be entirely similar to ASC-H. Some
of the issues to be considered while planning manage-
ment guidelines include: A. How to manage patients with
negative or unsatisfactory colposcopy results? B. Would a
conservative approach similar to LSIL or ASC-H cases be
optimum? C. Should endocervical sampling be obtained
if the colposcopic examination is satisfactory? D. Would a
cone biopsy similar to HSIL cases ever be indicated in
evaluation of LSIL-H category?
As the risk of high grade dysplasia associated with LSIL-H
is comparable with ASC-H, (Table 1, Figure 4) and the
association with lower incidence of negative results is sim-
ilar to LSIL, it is reasonable to apply some combination of
ASC-H and LSIL management guidelines. Possible appli-
cation of the HSIL approach at later stages of the algo-
rithm may be needed (Figure 5). For ASC-H and LSIL,
ASCCP recommends initial colposcopy [6,26]. If the col-
poscopic evaluation in the LSIL-H management algorithm
suggested in Figure 4 is negative, the cytology and biopsy
material should be reviewed. If the review leads to a
change in the interpretation, one should follow the
appropriate ASCCP algorithm [6,26]. As compared to the
choice of following either the LSIL or ASC-H algorithm,
the application of the suggested guidelines will require a
relatively small proportion (approximately 1 out of four
cases) of already rare LSIL-H cases to go through slightly
increased number of clinical encounters (Figure 5). These
guidelines may be evaluated comparatively with other
possible alternative combinations to refine it further as
indicated by follow up studies in the future.
Another alternative to LSIL-H as a distinct category is to
continue with current approach of communicating two
distinct interpretations, LSIL and ASC-H, for a given single
cervical specimen. Although this approach accommodates
2001 Bethesda System terminology, it has several disad-
vantages, including difficulties in organizing quality
assurance statistics. This, however, may interfere with the
management approach based on current ASCCP guide-
lines [6,22-25]. The current recommendation is to refer
both LSIL and ASC-H cases to colposcopy, but LSIL-H
cases have a significantly lower chance of negative results
(Table 1), and so relatively aggressive follow up steps may
be indicated at later stages of management. Another chal-
lenge is difficulty in verifying the risk of progression to
high grade dysplasia for two separate interpretations.
HPV DNA testing has been suggested to be a simple alter-
native with sensitivity and negative predictive value
approaching 100% for detecting HSIL [26-29]. The role of
HPV testing in primary screening of cervical cancer cur-
rently has been effective in the ASCUS category. Its role in
other categories is evolving. It has also been reported to be
helpful in ASC-H cases [27]. However, in LSIL-H, most of
the cases are expected to be positive for HPV testing and
so its role may be limited. In the current study, coinciden-
tal observation of HPV test results were available in 34 out
of total 88 LSIL-H cases. HPV testing was positive for high
risk HPV in 94% (32 out of 34). Cervical biopsy in two
Table 1: Biopsy results for LSIL, LSIL-H, ASC-H, and HSIL
Cytopathologic 
interpretation 
in SurePath™
Positive predictive value (PPV) for
Group A
Negative result on biopsy 
Group B
Low grade (HPV & CIN-1) 
result on biopsy
Group C
High grade (CIN-2 & CIN-3) 
result on biopsy 
Total (792)
1L S I L * 32% (179/557) 58% (323/557) 10% b(55/557) 100% (557)
2L S I L - H * 2 4 % a (21/88) 43%c (38/88) 33%b (29/88) 100% (88)
3A S C - H * 32%a (12/38) 37% c (14/38) 31%b (12/38) 100% (38)
4H S I L 5% (6/109) 26% (28/109) 69% (75/109) 100% (109)
* Positive predictive values between groups 1,2,&3 were compared by performing separate 2 × 3 Chi-square tests for rows 1 & 2 and for rows 2 & 
3. Applying the Bonferroni correction for multiple testing the significance level was adjusted to 0.025. The statistical comparison between LSIL and 
LSIL-H shows Chi-square value of 35.7 with p value less than 0.001, consistent with statistically significant difference between these two groups 
indicating they represent two separate entities. However, for LSIL-H and ASC-H the Chi-square is 0.87 with p value nearly equal to 1, consistent 
with lack of any significant difference between these two groups.
LSIL-Hb and ASC-Hb showed higher PPV for high grade dysplasia on biopsy, but prevalence of negative results was lower for LSIL-H, as compared to 
ASC-Ha. In summary, LSIL-H overlapped on one side with ASC-H for high grade risk, and with LSIL on other side for higher risk for low grade 
lesionc. The possibility of negative result with LSIL-Ha was intermediate between HSIL and LSIL or ASC-H.CytoJournal 2007, 4:7 http://www.cytojournal.com/content/4/1/7
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negative cases showed mild dysplasia with HPV in one
(negative for both low-risk and high-risk HPV) and high
grade dysplasia- not graded in the other (negative for
high-risk HPV but positive for low-risk HPV). These find-
ings, although based on small numbers, suggest that HPV
testing is not a useful ancillary test in the management of
LSIL-H.
Other possible ancillary tests include ProExC [30,31] and
p16INK4A (p16) [19,28,29,32-35]. A few have reported role
of ProExC with Topoisomerase II alpha (TOP2A) and
minichromosome maintenance protein 2 (MCM2) in
detection of cervical high-grade squamous intraepithelial
lesions from cytologic samples [30,31]. The current litera-
ture supports the role of p16 in squamous dysplasia
[19,28,29,32-35]. The results of p16 on cell block sections
of cervical cytology specimens [36] can be interpreted
more objectively. The interpretation of the specific nuclear
immunoreactivity for p16 is consistent with HPV related
dysplasia. Nonspecific cytoplasmic staining may be
present in surgical pathology and cell block sections, but
this does not interfere with the evaluation of nuclear
immunoreactivity. However, in cytology smears, this non-
specific cytoplasmic staining interferes with evaluation of
nuclear immunoreactivity with certainty [37,38]. Initial
observations suggest that p16 may play a significant role
as ancillary test [19,32,37]. The role of these molecular
markers is evolving and may help in evaluation of LSIL-H
in future.
In conclusion, although LSIL-H as interpretation category
is not a unique biologic entity, it correlates with increased
risk of high grade dysplasia on biopsy. A pattern of biopsy
results, intermediate between LSIL and ASC-H but distinct
LSIL-H as category overlap with LSIL and ASC-H, but was distinct from HSIL Figure 4
LSIL-H as category overlap with LSIL and ASC-H, but was distinct from HSIL. As compared to the LSIL interpreta-
tions; LSIL-H and ASC-H showed greater association with high grade dysplasia on biopsy. Compared to LSIL and ASC-H; inci-
dence of negative biopsy results was lower with LSIL-H. However, as compared to HSIL group, LSIL-H had higher incidence of 
negative results. LSIL-H had higher association with low grade lesion than ASC-H.
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from HSIL, justifies LSIL-H as a separate group for optimal
clinical management (Figure 5) with possible application
of molecular events such as p16 in the future.
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Table 2: Pattern of results in follow up biopsies- comparative review of literature
Study Cytology method 
used in the study
Total number of 
cases studied
Number of cases with biopsy High grade dysplasia (CIN2 & above) on biopsy
LSIL LSIL-H ASC-H HSIL LSIL % (n) LSIL-H % (n) ASC-H % (n) HSIL % (n)
1 Current study 
[11]
SurePath™¶ 77,979 LSIL-H 146 
(0.19%) (12 months)
557 88 38 109 10% (55) 33% (29) 31% (12) 69% (75)
2 Nasser et al 2003 
[1]
Not stated Not stated (12 
months)
150 144 X X 15% (23) 29% (42) X X
3 Kir et al 2004 [2] Not stated 21,342 (2 year) 27 13 X X 11% (3) 61% (8) X X
4 McGrath et al § 
2000 [12]
Not stated 48,687 LSIL- 108 
(0.2%) (14.5 months)
X 58 X X X 59% (34) X X
5 Elsheikh et al 2006 
[14]
ThinPrep®* 129,911 LSIL- 194 
(015%) (25 months)
575 59 110 289 13% (75) 41% (24) 45% (49) 74% (214)
6 Booth et al 2005 
[13] (Abstract)
Not stated 21,082 LSIL-H 31 
(0.15%)
X X X X 10% (5) 45% (9) X 69% (29)
7 D'Furio et al 2005 
[17] (Abstract)
ThinPrep®*N o t  s t a t e d X 8 3 3 7 X X4 0 %6 2 %X
8 Underwood et al 
2006 [15] 
(Abstract)
ThinPrep®&Conventi
onal
130,761
A. ThinPrep®* 
(127,929)
B. Conventional 
(2832)
LSIL-H 270 (0.2%)
(24 months)
X X X X 13% (163) 36% (70) 38% (93) 66% (170)
9 O'Brien et al 2006 
[16] (Abstract)
ThinPrep®* A. Pre-imaging: 
76,365
(50 LSIL-H 0.065%)
B. Post-
imaging:63,812
(139 LSIL-H 0.22%)
X A- 40 B- 107 X X X A- 23%(9) 
B- 37%(39)
XX
10 Jain et al 2005 [18] 
(Abstract)
Not stated Total 67 LSIL-H
A- Few :
3 or more ASC-H 
cells
B- Rare:
1 to 2 ASC-H cells
X 48 A. 22 B. 26 X X X A- 64% (14/22) 
B- 23% (6/26)
X 56% (9/16)
§This study used different terminology as mild to moderate dysplasia but implied non-definitive interpretation equivalent to LSIL-H; ¶SurePath™ 
((TriPath Imaging, Inc. Burlington, NC, USA)), *
ThinPrep® (Cytyc Corporation, Marlborough, MA, USA), m, months; yrs, years.
X Blanks represent lack of that information in the corresponding published data.CytoJournal 2007, 4:7 http://www.cytojournal.com/content/4/1/7
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